The KRAS G12C mutation is found in approximately 3% of all colorectal cancer cases and 1% to 2% of pancreatic adenocarcinoma cases, according to Hao Xie, MD, PhD, a medical oncologist at Mayo ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor ...

Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C inhibitors, ...

Bottom line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...

Bottom Line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...